Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey
Hüseyin Aytaç ErdemPervin Ekren KorkmaDerya ÇağlayanMeltem Işıkgöz TaşbakanTansu YamazhanMehmet Sezai TaşbakanAbdullah SayinerGökengin DenizPublished in: Turkish journal of medical sciences (2021)
This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.